NCT01249365View on ClinicalTrials.gov

The Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study

PHASE3CompletedINTERVENTIONAL
Enrollment

199

Participants

Timeline

Start Date

January 24, 2011

Primary Completion Date

January 10, 2017

Study Completion Date

January 10, 2017

Conditions
Infections, Papillomavirus
Interventions
BIOLOGICAL

GSK580299 (Cervarix)

3-dose schedule intramuscularly vaccination

Trial Locations (15)

3052

GSK Investigational Site, Parkville

109263

GSK Investigational Site, Moscow

115478

GSK Investigational Site, Moscow

117997

GSK Investigational Site, Moscow

119074

GSK Investigational Site, Singapore

190020

GSK Investigational Site, Saint Petersburg

199034

GSK Investigational Site, Saint Petersburg

229899

GSK Investigational Site, Singapore

620073

GSK Investigational Site, Yekaterinburg

Unknown

GSK Investigational Site, Perth

2805-267 Almada

GSK Investigational Site, Almada

3000-075 Coimbra

GSK Investigational Site, Coimbra

1200-831 Lisboa

GSK Investigational Site, Lisbon

4200-023 Porto

GSK Investigational Site, Porto

2910-446 Setúbal

GSK Investigational Site, Setúbal

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01249365 - The Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study | Biotech Hunter | Biotech Hunter